Presentation is loading. Please wait.

Presentation is loading. Please wait.

Left Ventricular Assist Device Destination Therapy Versus Extended Criteria Cardiac Transplant  Mani A. Daneshmand, MD, Keshava Rajagopal, MD, PhD, Brian.

Published byἩρὼ Γούσιος Modified over 5 years ago

Similar presentations

Presentation on theme: "Left Ventricular Assist Device Destination Therapy Versus Extended Criteria Cardiac Transplant  Mani A. Daneshmand, MD, Keshava Rajagopal, MD, PhD, Brian."— Presentation transcript:

1 Left Ventricular Assist Device Destination Therapy Versus Extended Criteria Cardiac Transplant 
Mani A. Daneshmand, MD, Keshava Rajagopal, MD, PhD, Brian Lima, MD, Nikta Khorram, BS, Laura J. Blue, NP, Andrew J. Lodge, MD, Adrian F. Hernandez, MD, Joseph G. Rogers, MD, Carmelo A. Milano, MD  The Annals of Thoracic Surgery  Volume 89, Issue 4, Pages (April 2010) DOI: /j.athoracsur Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Reasons for transplant ineligibility in each group. While advanced age was the most common reason for transplant ineligibility for both extended criteria–alternate list cardiac transplantation (EC-AL) and destination therapy with left ventricular assist device (DT-LVAD) groups, the DT-LVAD patients were more commonly ineligible due to obesity and pulmonary hypertension (*p < 0.05). (CRI = chronic renal insufficiency; DM = diabetes mellitus; EOD = end-organ dysfunction; HTN = hypertension.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 (A) Kaplan-Meier survival analysis comparing extended criteria–alternate list cardiac transplantation (EC-AL) patients (solid line) to destination therapy with left ventricular assist device (DT-LVAD) patients (dotted line) and REMATCH cohort (dashed line). Inclusion of EC-AL patients is conditional on survival to transplantation. The DT-LVAD patients significantly outperform the REMATCH cohort both in short-term (30-day and 1-year) and midterm (3-year) survival. The EC-AL patient survival is superior to that of DT-LVAD patients at 3 years. (B) Kaplan-Meier survival analysis comparing EC-AL (solid line) to DT-LVAD (dotted line) wherein EC-AL patients are accounted for at time of listing for transplantation. Survival of EC-AL and DT-LVAD patients is similar at all time points. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Reasons for transplant ineligibility in each propensity-matched group: extended criteria–alternate list cardiac transplantation (EC-AL) patients (black bars) and destination therapy with left ventricular assist device (DT-LVAD) patients (gray bars). Advanced age and obesity remain the most common reasons for transplant ineligibility. (CRI = chronic renal insufficiency; DM = diabetes mellitus; EOD = end-organ dysfunction; HTN = hypertension.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions

5 Fig 4 Kaplan-Meier survival estimates comparing matched groups of destination therapy with left ventricular assist device (DT-LVAD) patients (dotted line) and extended criteria–alternate list cardiac transplantation (EC-AL) patients (solid line). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions

6 Fig 5 Kaplan-Meier survival estimates comparing matched groups of destination therapy with left ventricular assist device (DT-LVAD) patients (dotted line) and extended criteria–alternate list cardiac transplantation (EC-AL) patients (solid line) after removing the HeartMate XVE patients from the DT-LVAD group. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Left Ventricular Assist Device Destination Therapy Versus Extended Criteria Cardiac Transplant  Mani A. Daneshmand, MD, Keshava Rajagopal, MD, PhD, Brian."

Similar presentations

Fenton H. McCarthy, MD, Dale Kobrin, BA, J. Eduardo Rame, MD, Peter W

Fenton H. McCarthy, MD, Dale Kobrin, BA, J. Eduardo Rame, MD, Peter W
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,
Long-Term Outcome of Coronary Artery Bypass Grafting in Patients With Left Ventricular Dysfunction  Paolo Nardi, MD, PhD, Antonio Pellegrino, MD, Antonio.

Long-Term Outcome of Coronary Artery Bypass Grafting in Patients With Left Ventricular Dysfunction  Paolo Nardi, MD, PhD, Antonio Pellegrino, MD, Antonio.
Survival on the Heart Transplant Waiting List: Impact of Continuous Flow Left Ventricular Assist Device as Bridge to Transplant  Jaimin R. Trivedi, MD,

Survival on the Heart Transplant Waiting List: Impact of Continuous Flow Left Ventricular Assist Device as Bridge to Transplant  Jaimin R. Trivedi, MD,
Jeevan Nagendran, MD, Colleen M. Norris, PhD, Michelle M

Jeevan Nagendran, MD, Colleen M. Norris, PhD, Michelle M
Long-Term Follow-Up of Cardiac Rhythm in 320 Patients After the Cox-Maze III Procedure for Atrial Fibrillation  Anders Albåge, MD, PhD, Birgitta Johansson,

Long-Term Follow-Up of Cardiac Rhythm in 320 Patients After the Cox-Maze III Procedure for Atrial Fibrillation  Anders Albåge, MD, PhD, Birgitta Johansson,
Improved Early Survival With a Nonsternotomy Approach for Continuous-Flow Left Ventricular Assist Device Replacement  Matthew A. Schechter, MD, Chetan.

Improved Early Survival With a Nonsternotomy Approach for Continuous-Flow Left Ventricular Assist Device Replacement  Matthew A. Schechter, MD, Chetan.
Laura Harvey, MD, Christopher Holley, MD, Samit S

Laura Harvey, MD, Christopher Holley, MD, Samit S
Clinical Profile and Natural History of 453 Nonsurgically Managed Patients With Severe Aortic Stenosis  Padmini Varadarajan, MD, Nikhil Kapoor, MD, Ramesh.

Clinical Profile and Natural History of 453 Nonsurgically Managed Patients With Severe Aortic Stenosis  Padmini Varadarajan, MD, Nikhil Kapoor, MD, Ramesh.
Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis  Andrew J. Graham, MD, MS, Fiona M. Shrive,

Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis  Andrew J. Graham, MD, MS, Fiona M. Shrive,
Michael E. Halkos, MD, Patrick Kilgo, MS, Omar M

Michael E. Halkos, MD, Patrick Kilgo, MS, Omar M
Does Diabetes Affect the Postoperative Outcomes After Total Arterial Off-Pump Coronary Bypass Surgery in Multivessel Disease?  Jae-Sung Choi, MD, PhD,

Does Diabetes Affect the Postoperative Outcomes After Total Arterial Off-Pump Coronary Bypass Surgery in Multivessel Disease?  Jae-Sung Choi, MD, PhD,
Robert E. Merritt, MD, Richard I. Whyte, MD, Nicole T

Robert E. Merritt, MD, Richard I. Whyte, MD, Nicole T
Influence of Pulmonary Hypertension on Patients With Idiopathic Pulmonary Fibrosis Awaiting Lung Transplantation  Don Hayes, MD, MS, Sylvester M. Black,

Influence of Pulmonary Hypertension on Patients With Idiopathic Pulmonary Fibrosis Awaiting Lung Transplantation  Don Hayes, MD, MS, Sylvester M. Black,
Jacob N. Schroder, MD, Mani A. Daneshmand, MD, Nestor R

Jacob N. Schroder, MD, Mani A. Daneshmand, MD, Nestor R
Less Is More in Post Pediatric Heart Transplant Care

Less Is More in Post Pediatric Heart Transplant Care
Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer  Robert E. Merritt, MD, Chuong D. Hoang, MD,

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer  Robert E. Merritt, MD, Chuong D. Hoang, MD,
Operative Results and Outcomes in Children With Shone's Anomaly

Operative Results and Outcomes in Children With Shone's Anomaly
Hanan A. Tanash, PhD, Gerdt C. Riise, PhD, Magnus P

Hanan A. Tanash, PhD, Gerdt C. Riise, PhD, Magnus P
Surgical Ventricular Restoration for Advanced Congestive Heart Failure: Should Pulmonary Hypertension Be a Contraindication?  Nishant D. Patel, BA, Jason.

Surgical Ventricular Restoration for Advanced Congestive Heart Failure: Should Pulmonary Hypertension Be a Contraindication?  Nishant D. Patel, BA, Jason.

Similar presentations

Ads by Google